PMID- 28836861
OWN - NLM
STAT- MEDLINE
DCOM- 20180627
LR  - 20220408
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 1
DP  - 2018 Jan
TI  - Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for 
      type 2 diabetes therapy.
PG  - 1-10
LID - 10.1080/03007995.2017.1372118 [doi]
AB  - BACKGROUND: Diabetes mellitus is a serious and increasingly prevalent condition 
      in Canada and around the world. Treatment strategies have become increasingly 
      complex, with a widening array of pharmacological agents available for glycemic 
      management in type 2 diabetes mellitus (T2DM). New therapies that act in concert 
      with available basal insulins may represent alternatives to basal insulin 
      intensification with prandial or pre-mixed insulin. Glucagon-like peptide-1 
      receptor agonists (GLP-1 RAs) have recently shown promise as useful additions to 
      basal insulin, with significant reductions in glycated hemoglobin and potentially 
      beneficial effects on body weight. This review will focus on pivotal clinical 
      trials to assess the potential benefits of adding prandial GLP-1 RAs to basal 
      insulin in patients with T2DM. METHODS: Clinical studies combining prandial GLP-1 
      RAs and basal insulin (published between 2011 and July 2017) were identified and 
      reviewed in PubMed, the Cochrane Central Register of Clinical Trials (Issue 6, 
      June 2017), and clinicaltrials.gov. RESULTS: Most of the studies presented in 
      this review show that the addition of a prandial GLP-1 RA to basal insulin 
      results in equal or slightly superior efficacy compared to the addition of 
      prandial insulin, together with weight loss and less hypoglycemia. CONCLUSIONS: 
      The results of the studies suggest that a prandial GLP-1 RA as an add-on to basal 
      insulin may be a safe and effective treatment intensification option (vs 
      basal-plus or basal-bolus insulin).
FAU - Goldenberg, Ronald M
AU  - Goldenberg RM
AD  - a LMC Diabetes & Endocrinology , Thornhill , ON , Canada.
FAU - Berard, Lori
AU  - Berard L
AD  - b Winnipeg Regional Health Authority, Health Sciences Centre, Department of 
      Medicine , Section of Endocrinology, University of Manitoba , Winnipeg , MB , 
      Canada.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170928
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
SB  - IM
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/administration & dosage/*therapeutic use
OTO - NOTNLM
OT  - Diabetes guidelines
OT  - insulin
OT  - prandial glucagon-like peptide-1 receptor agonists
OT  - type 2 diabetes mellitus
EDAT- 2017/08/25 06:00
MHDA- 2018/06/28 06:00
CRDT- 2017/08/25 06:00
PHST- 2017/08/25 06:00 [pubmed]
PHST- 2018/06/28 06:00 [medline]
PHST- 2017/08/25 06:00 [entrez]
AID - 10.1080/03007995.2017.1372118 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 Jan;34(1):1-10. doi: 10.1080/03007995.2017.1372118. Epub 
      2017 Sep 28.